Oral or nasal anti-CD3 antibody administration can induce CD4+LAP (latency-associated peptide)+ Tregs that suppress experimental autoimmune diseases in a TGF-β-dependent manner [109,110]. Here, TGFB1 is linked to autoimmune disease.